• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel

Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel

Roles at LPBI: UPDATED on 8/15/2020

Science: AI in healthcare, AI in medical diagnosis, BioIT Bioinformatics, Biomarkers and medical diagnostics, Glycobiology, Cancer and current Therapeutics, Microbiome, Clinical diagnostics, Diagnostic immunology

Business:

  1. Biotech venture creation
  2. Joint Venture 2.0 LPBI Group (30%) with ABI-Lab (70%)

Business Development responsibilities @LPBI: Biotech in Israel, in Switzerland and in other countries in Europe

 

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

    Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health

    • Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery 
    • Inputs for Proof of Concept are the following three:

    (1) Top 12 articles by views (all domains)

    (2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1

    (3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

 

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

TNS #1: See above

TNS #2: EXEMPT due to conflict of interests

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Dr. Nir for Drug Discovery

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • PENDING

 

On record:

  • Biotech Ecosystem in Israel – Introductions: Aviva and Biotech CEOs
  • DayOne Basel – https://www.dayone.swiss/dayone.html – The Swiss Innovation Hub for Precision Medicine – Introductions of LPBI Group
  • 2Q 2020 Ofer will bring to LPBI Group’s new prospects for the Exit

Domains of Expertise

  • AI in healthcare
  • AI in medical diagnosis
  • BioIT Bioinformatics
  • Biomarkers and medical diagnostics
  • Glycobiology 
  • Biotech venture creation
  • Cancer and current Therapeutics
  • Microbiome
  • Clinical diagnostics
  • Diagnostic immunology

Ofer Markman, PhD

oferm2015@gmail.com

+972-523-275720

Haifa, Israel  

BIO 

Dr. Markman is a serial entrepreneur with over 20 years of experience serving as CEO or CXO for several companies in the biotechnology, technology, and food technology space. He has raised over $70M in venture capital financing for companies that have had various successful exits, including some companies that remain private and others that have had an IPO. Most notably he was a founding partner of Procognia that has raised over $50M in 2007.

Dr Markman was a lecturer of Glycotechnology at the Ort Braude Engineering College  and is leading a Science internship program reaching its 80 interns in 3 years land-mark goal

Ofer Published articles and invented multiple patents, Products he has led to markets were sold at over 8 digit dollars of revenue worldwide. As a leader in acceleration plans Dr Markman assisted dozens of entrepreneurs and young companies reach their business goals.

Dr. Markman holds a PhD in Chemistry from Boston College, and worked with Nobel Laureate Ada Yonath for his Master’s Degree.

 

  • Published 10 journal articles
  • Inventor in 14 granted patents
  • Major (res.) in Military Intelligence and HLS
  • 2x Entrepreneur, raised $30M for two companies founded.

Experience

June 2014 – Present        

Hub Manager, Global Medical Centers of Excellence (GMCE), Haifa Life Sciences Hub Innovation 

  • Managing the Israeli branch of Global Medical Centers of Excellence, a US-based innovation facility that initiates and operates medical centers worldwide, including the Caribbean, Jamaica, Dubai and Ethiopia. Our center escorts start-up companies from seed stage to spin-off and new markets entry in all business aspects including market research, strategic consulting, business modeling and business planning.
  • Developed and executed a strong internship program with so far over 50 interns and over 15 companies that outsourced the internship to us. Over 40 high quality projects submitted.
  • Three Letters of Intent (LOI) received from top investors to build hospitals.
  • Developed and executed a top strategy workshop so far with over 10 clients, including companies from France and the Caribbean Islands.
  • Developed a network of investors reviewing investment opportunities in Israel, the Caribbean Islands, Canada and Europe.
  • Developed and ran a Technology Competition for technology in the aid of senior citizens (3rd Age)
  • Ran one Hakathon (Arkathon IL 2019) https://gmce-inc.wixsite.com/gmce-haifa-hub/post/2019-arkathon

November 2016 – Present         ASPARNA LTD          EVP of Business Development

  • Joined Asparna at the request of its founder to lead the business pivot of Asparna from Research and B2C to Commercialization and B2B.
  • Responsible for business development activities including business modeling and funding
  • Participated in the entire business pivot strategic planning cycle with Asparna’s Founder, Mr. Laron.
  • Responsible for oversight and PMO execution of all customer-facing projects,
  • External relations include upcoming projects with the Ministry of Health, Israeli Post company, Matrix Israel and others.
  • Elected as member of the Board of Directors in recognition for accomplishments on behalf of Asparna

December 2014 – September 2016       Olive Grove Ventures     Partner, CTO

  • Olive Grove Ventures (OGV) is a growth engine that cultivates successful sustainable businesses from Israeli innovation.
  • OGV develops and manages platforms that bridge the Israeli technology – U.S. market gap.
  • Was instrumental in co-founding MilkPro, a data-mining technology company combining dairy, food, environmental and social aspects of the Whey industry.
  • Initiated with other players a collaboration between Tel Chai College and Rutgers University Food Innovation Center.

September 2006 – September 2016      Ort Braude          Biotechnology Faculty

  • Lectured for 10 years on Glyco-Technology at Ort Braude College.
  • Developed courses curriculum for several courses
  • Mentored students in credited internship and entrepreneurial projects

2000 – 2007       ProCognia Ltd              Founder, CSO

ProCognia is a Biotechnology Company, providing analytical services to biopharmaceutical and biosimilars companies.

  • Co-founder of ProCognia,
  • Managed the Science Operations and new technology development and fund raised over $25M for bio-informatics in several rounds.
  • Assisted our customers in directing their products towards optimal glycosylation, for improved efficacy and safety.
  • For Biosimilars manufacturers, our services directed clone and cell line selection and manufacturing conditions towards a product with glycosylation profiles similar to the original product, as required by the regulatory authorities.

 

 

2005 – 2008       Nutricognia Ltd          Founder

  • A spin off from ProCognia, conducting  analysis in the Nutraceuticals and Sports nutrition field

Others spin offs including:

  • NutriCognia
  • Savyon Diagnostics
  • Healthcare Technologies Ltd

 

Education

Postdoctoral Appointments

1998 – 2000       Hadassah Hebrew University,  School of Medicine          Visiting Researcher

  • Post-doctoral position

1990 – 1991       Universite Paris Sud (Paris XIII) Visiting Researcher

  • Post-graduate position, Weizmann Europe Fellowship

Academic Education and Degrees

1991 – 1996       Boston College             Ph.D. in Chemistry

1989 – 1990       Weizmann Institute of Science     M.Sc. In Life Sciences

  • Thesis: Crystal Growth of Insulin and various antibodies and the interaction between them.

Advisors:

Prof. Ada Yonath – Nobel prize in chemistry 2009

Prof. Irun Cohen

Membership in Professional Associations

  • LANES
  • GSA

Social Causes and Impact activities

  • Founder of The Ayala K Markman Fund for Good Competition (2018-current)

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,459 other subscribers
  • Recent Posts

    • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
    • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
    • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
    • Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
    • Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
    • Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
    • Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
    • Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: